{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:25:31Z","timestamp":1787538331084,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,23]]},"DOI":"10.7759\/cureus.115044","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:03:27Z","timestamp":1787537007000},"source":"Crossref","is-referenced-by-count":0,"title":["Endocrinologically Silent Crooke Cell Adenoma With Apoplexy Causing Oculomotor Palsy: An Uncommon and Underrecognised Entity"],"prefix":"10.7759","author":[{"given":"Ernest Zhi Yu","family":"Tay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vint Seng Hein Lin Htut","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Char Loo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira Siyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiong Wen","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Peng","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-022-2673-6","article-title":"Overview of the 2022 WHO classification of pituitary adenomas\/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives","volume":"42","author":"Wan XY","year":"2022","unstructured":"Wan XY, Chen J, Wang JW, Liu YC, Shu K, Lei T. Overview of the 2022 WHO classification of pituitary adenomas\/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives. Curr Med Sci. 2022, 42:1111-8. 10.1007\/s11596-022-2673-6","journal-title":"Curr Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1468727","article-title":"Case report: refractory hypokalemia as a clinical manifestation of Crooke's cell adenoma","volume":"12","author":"Kattah L","year":"2025","unstructured":"Kattah L, Bustamante L, Sanabria D, Salazar J. Case report: refractory hypokalemia as a clinical manifestation of Crooke's cell adenoma. Front Med (Lausanne). 2025, 12:1468727. 10.3389\/fmed.2025.1468727","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.947085","article-title":"Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: case series and literature review","volume":"13","author":"Zhu D","year":"2022","unstructured":"Zhu D, Wang Z, Tian T, et al.. Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: case series and literature review. Front Endocrinol (Lausanne). 2022, 13:947085. 10.3389\/fendo.2022.947085","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200310000-00005","article-title":"Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma","volume":"27","author":"George DH","year":"2003","unstructured":"George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003, 27:1330-6. 10.1097\/00000478-200310000-00005","journal-title":"Am J Surg Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2023.09.076","article-title":"Crooke cell adenoma confers poorer endocrinological outcomes compared with corticotroph adenoma: results of a multicenter, international analysis","volume":"180","author":"Findlay MC","year":"2023","unstructured":"Findlay MC, Drexler R, Azab M, et al.. Crooke cell adenoma confers poorer endocrinological outcomes compared with corticotroph adenoma: results of a multicenter, international analysis. World Neurosurg. 2023, 180:e376-91. 10.1016\/j.wneu.2023.09.076","journal-title":"World Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-025-01566-5","article-title":"USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma","volume":"28","author":"Kober P","year":"2025","unstructured":"Kober P, Szczepaniak M, P\u0119kul M, et al.. USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma. Pituitary. 2025, 28:107. 10.1007\/s11102-025-01566-5","journal-title":"Pituitary"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease","volume":"174","author":"Hayashi K","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, et al.. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Eur J Endocrinol. 2016, 174:213-26. 10.1530\/EJE-15-0689","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet C","year":"2015","unstructured":"Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary apoplexy. Endocr Rev. 2015, 36:622-45. 10.1210\/er.2015-1042","journal-title":"Endocr Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092508","article-title":"Pituitary apoplexy: an updated review","volume":"13","author":"Iglesias P","year":"2024","unstructured":"Iglesias P. Pituitary apoplexy: an updated review. J Clin Med. 2024, 13:2508. 10.3390\/jcm13092508","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406093302306","article-title":"Hypopituitarism","volume":"330","author":"Vance ML","year":"1994","unstructured":"Vance ML. Hypopituitarism. N Engl J Med. 1994, 330:1651-62. 10.1056\/NEJM199406093302306","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00761-2","article-title":"Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report","volume":"21","author":"de Silva NL","year":"2021","unstructured":"de Silva NL, Somasundaram N, Constantine R, Kularatna H. Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report. BMC Endocr Disord. 2021, 21:93. 10.1186\/s12902-021-00761-2","journal-title":"BMC Endocr Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1385\/ep:13:3:245","article-title":"Crooke's hyalinization in silent corticotroph adenoma: report of two cases","volume":"13","author":"Roncaroli F","year":"2002","unstructured":"Roncaroli F, Faustini-Fustini M, Mauri F, Asioli S, Frank G. Crooke's hyalinization in silent corticotroph adenoma: report of two cases. Endocr Pathol. 2002, 13:245-9. 10.1385\/ep:13:3:245","journal-title":"Endocr Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.07.233","article-title":"Clinically silent adrenocorticotropic hormone-positive crooke cell adenoma: case report and review of literature","volume":"119","author":"Todnem N","year":"2018","unstructured":"Todnem N, Ward A, Segar S, Rojiani AM, Rahimi SY. Clinically silent adrenocorticotropic hormone-positive crooke cell adenoma: case report and review of literature. World Neurosurg. 2018, 119:197-200. 10.1016\/j.wneu.2018.07.233","journal-title":"World Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2018-0347","article-title":"Clinically silent adrenocorticotropic hormone-secreting Crooke cell adenoma presenting as unilateral ear pain","volume":"5","author":"Khatri KJ","year":"2019","unstructured":"Khatri KJ, Javanmard P, Pawha PS, Miller JD. Clinically silent adrenocorticotropic hormone-secreting Crooke cell adenoma presenting as unilateral ear pain. AACE Clin Case Rep. 2019, 5:e150-3. 10.4158\/ACCR-2018-0347","journal-title":"AACE Clin Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.10.232","article-title":"Apoplectic silent Crooke cell adenoma with adjacent pseudoaneurysms: causation or bystander?","volume":"122","author":"Krug RG 2nd","year":"2019","unstructured":"Krug RG 2nd, Chang AY, Raghunathan A, Van Gompel JJ. Apoplectic silent Crooke cell adenoma with adjacent pseudoaneurysms: causation or bystander?. World Neurosurg. 2019, 122:480-4. 10.1016\/j.wneu.2018.10.232","journal-title":"World Neurosurg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.70121","article-title":"Crooke cell adenoma: is its aggressiveness overestimated? Evidence from a single-centre experience","volume":"104","author":"Muradov I","year":"2026","unstructured":"Muradov I, Sahin S, Akpinar S, et al.. Crooke cell adenoma: is its aggressiveness overestimated? Evidence from a single-centre experience. Clin Endocrinol (Oxf). 2026, 104:647-56. 10.1111\/cen.70121","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2021.11.049","article-title":"Functioning Crooke cell adenomas: case series and literature review","volume":"158","author":"Giraldi EA","year":"2022","unstructured":"Giraldi EA, Neill SG, Mendoza P, Saindane A, Oyesiku NM, Ioachimescu AG. Functioning Crooke cell adenomas: case series and literature review. World Neurosurg. 2022, 158:e754-65. 10.1016\/j.wneu.2021.11.049","journal-title":"World Neurosurg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3171\/2020.10.JNS203236","article-title":"Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence","volume":"135","author":"Strickland BA","year":"2021","unstructured":"Strickland BA, Shahrestani S, Briggs RG, et al.. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence. J Neurosurg. 2021, 135:1706-13. 10.3171\/2020.10.JNS203236","journal-title":"J Neurosurg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed S","year":"2020","unstructured":"Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020, 382:937-50. 10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04068.x","article-title":"Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences","volume":"75","author":"Pal A","year":"2011","unstructured":"Pal A, Capatina C, Tenreiro AP, et al.. Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences. Clin Endocrinol (Oxf). 2011, 75:501-4. 10.1111\/j.1365-2265.2011.04068.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0547","article-title":"Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide","volume":"66","author":"Tanaka S","year":"2019","unstructured":"Tanaka S, Yamamoto M, Morita M, et al.. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. Endocr J. 2019, 66:701-8. 10.1507\/endocrj.EJ18-0547","journal-title":"Endocr J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3171\/2014.10.JNS141720","article-title":"Apoplexy of pituitary adenomas: the perfect storm","volume":"122","author":"Oldfield EH","year":"2015","unstructured":"Oldfield EH, Merrill MJ. Apoplexy of pituitary adenomas: the perfect storm. J Neurosurg. 2015, 122:1444-9. 10.3171\/2014.10.JNS141720","journal-title":"J Neurosurg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.03.152","article-title":"Gamma knife radiosurgery in patients with Crooke cell adenoma","volume":"138","author":"Snyder MH","year":"2020","unstructured":"Snyder MH, Shabo L, Lopes MB, Xu Z, Schlesinger D, Sheehan JP. Gamma knife radiosurgery in patients with Crooke cell adenoma. World Neurosurg. 2020, 138:e898-904. 10.1016\/j.wneu.2020.03.152","journal-title":"World Neurosurg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.39","article-title":"Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide","volume":"2","author":"Asimakopoulou A","year":"2014","unstructured":"Asimakopoulou A, Tzanela M, Koletti A, Kontogeorgos G, Tsagarakis S. Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide. Clin Case Rep. 2014, 2:1-3. 10.1002\/ccr3.39","journal-title":"Clin Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0414","article-title":"High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease","volume":"161","author":"Takeshita A","year":"2009","unstructured":"Takeshita A, Inoshita N, Taguchi M, et al.. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol. 2009, 161:553-9. 10.1530\/EJE-09-0414","journal-title":"Eur J Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2016.0060","article-title":"Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment","volume":"67","author":"Kurowska M","year":"2016","unstructured":"Kurowska M, Tarach JS, Malicka J, Zieli\u0144ski G, Maksymowicz M, Denew P. Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment. Endokrynol Pol. 2016, 67:526-33. 10.5603\/EP.2016.0060","journal-title":"Endokrynol Pol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13075","article-title":"Pituitary apoplexy - bespoke patient management allows good clinical outcome","volume":"85","author":"Giritharan S","year":"2016","unstructured":"Giritharan S, Gnanalingham K, Kearney T. Pituitary apoplexy - bespoke patient management allows good clinical outcome. Clin Endocrinol (Oxf). 2016, 85:415-22. 10.1111\/cen.13075","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.620005","article-title":"Significance of Crooke's hyaline change in nontumorous corticotrophs of patients with Cushing disease","volume":"12","author":"Akirov A","year":"2021","unstructured":"Akirov A, Larouche V, Shimon I, et al.. Significance of Crooke's hyaline change in nontumorous corticotrophs of patients with Cushing disease. Front Endocrinol (Lausanne). 2021, 12:620005. 10.3389\/fendo.2021.620005","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2493","article-title":"Crooke's changes in Cushing's syndrome depends on degree of hypercortisolism and individual susceptibility","volume":"100","author":"Oldfield EH","year":"2015","unstructured":"Oldfield EH, Vance ML, Louis RG, Pledger CL, Jane JA Jr, Lopes MB. Crooke's changes in Cushing's syndrome depends on degree of hypercortisolism and individual susceptibility. J Clin Endocrinol Metab. 2015, 100:3165-71. 10.1210\/JC.2015-2493","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","article-title":"Non-functioning pituitary adenomas","author":"Drummond JB","unstructured":"Drummond JB, Ribeiro-Oliveira A Jr, Soares BS. Non-functioning pituitary adenomas. Endotext. 2000 (ed): MDText.com, Inc., South Dartmouth, MA;"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2012.00599.x","article-title":"Clinicopathological correlations in pituitary adenomas","volume":"22","author":"Mete O","year":"2012","unstructured":"Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol. 2012, 22:443-53. 10.1111\/j.1750-3639.2012.00599.x","journal-title":"Brain Pathol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2013.06.002","article-title":"Therapeutic implications of accurate classification of pituitary adenomas","volume":"30","author":"Mete O","year":"2013","unstructured":"Mete O, Asa SL. Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol. 2013, 30:158-64. 10.1053\/j.semdp.2013.06.002","journal-title":"Semin Diagn Pathol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2021-0479-OA","article-title":"Transcription factor immunohistochemistry in the classification of pituitary neuroendocrine tumor\/adenoma: proposal in a limited-resource setting","volume":"148","author":"Sood R","year":"2024","unstructured":"Sood R, Chatterjee D, Dutta P, Radotra BD. Transcription factor immunohistochemistry in the classification of pituitary neuroendocrine tumor\/adenoma: proposal in a limited-resource setting. Arch Pathol Lab Med. 2024, 148:178-89. 10.5858\/arpa.2021-0479-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0091-OA","article-title":"The role of T-box transcription factor in a pituitary adenoma diagnostic algorithm","volume":"145","author":"McDonald WC","year":"2021","unstructured":"McDonald WC, McDonald KN, Helmer JA, Ho B, Wang A, Banerji N. The role of T-box transcription factor in a pituitary adenoma diagnostic algorithm. Arch Pathol Lab Med. 2021, 145:592-8. 10.5858\/arpa.2020-0091-OA","journal-title":"Arch Pathol Lab Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516747-endocrinologically-silent-crooke-cell-adenoma-with-apoplexy-causing-oculomotor-palsy-an-uncommon-and-underrecognised-entity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:03:28Z","timestamp":1787537008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516747-endocrinologically-silent-crooke-cell-adenoma-with-apoplexy-causing-oculomotor-palsy-an-uncommon-and-underrecognised-entity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.115044","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}